Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS3351 in Advanced Non-Small Cell Lung Cancer and EGFR Mutations
NCT05765734Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- May 2023
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 1, open-label trial of TAS3351 in non-small cell lung cancer (NSCLC) (9 arms), sponsored by Taiho Oncology. Primary endpoints: Treatment Emergent Adverse Events up to 21.7 months, Dose Limiting Toxicities at 21 days and 1 more. Started May 2023; status: terminated.
02
Drugs
TAS3351
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05765734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765734.